Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TD 8954

Drug Profile

TD 8954

Alternative Names: TAK 954; TD8954

Latest Information Update: 11 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance
  • Developer Takeda; Theravance; Theravance Biopharma
  • Class Antidementias; Benzimidazoles; Carboxylic acids; Gastrokinetics; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic gastroparesis; Gastrointestinal motility disorders
  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Feb 2019 Millennium Pharmaceuticals plans a phase II trial for Gastrointestinal disorders (in patients undergoing open or laparoscopic-assisted partial small- or large-bowel resection) in March 2019 in USA and Europe (IV) (NCT03827655)
  • 07 Dec 2018 Takeda completes a phase I trial in Healthy volunteers (IV) (NCT03296787)
  • 01 Sep 2018 Takeda completes a phase I trial in Gastrointestinal motility disorders (in patients and in healthy volunteers) in Czech Republic (IV) (NCT03277274)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top